Justin P. Kline to Immunotherapy
This is a "connection" page, showing publications Justin P. Kline has written about Immunotherapy.
Connection Strength
1.360
-
The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020 02 20; 135(8):523-533.
Score: 0.498
-
Mechanisms of Immune Tolerance in Leukemia and Lymphoma. Trends Immunol. 2017 07; 38(7):513-525.
Score: 0.411
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer. 2020 12; 8(2).
Score: 0.132
-
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015 Oct; 21(10):1209-15.
Score: 0.091
-
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs. 2010 Dec; 11(12):1354-9.
Score: 0.066
-
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
Score: 0.064
-
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91.
Score: 0.058
-
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma. Ann Hematol. 2024 Jan; 103(1):185-198.
Score: 0.040